• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Safety Labeling updates and new warnings

Article

The manufacturer of ato-moxetine (Strattera, Lilly) was directed by FDA to revise the prescribing information for the drug to include a black box warning and additional statements that alert healthcare providers of an increased risk of suicidal thinking in children and adolescents being treated with this medication.

Related Content
© 2024 MJH Life Sciences

All rights reserved.